KRN125 for Mobilization of Hematopoietic Stem Cells

Phase 2 Completed 35 enrolled Kyowa Kirin, Inc.

NaSingle-groupOpen-labelTreatment

Summary

Data collection to evaluate safety and effect of hematopoietic stem cell mobilization into the peripheral blood after a single subcutaneous (SC) dose of KRN125(Pegfilgrastim)in healthy adults.

Timeline

Start: 2019-05-28
Primary completion: 2020-07-21
Completion: 2020-08-28

Publications

Goto H, Sugita J, Hasegawa Y, Hayasaka K, Sunagoya K, Hatase R, Nishida M, Ichihashi Y, Odera M, Senjo H, Yokoyama S, Ara T, Shiratori S, Endo T, Hino M, Maeda Y, Sawa M, Sato N, Teshima T. Efficacy and Safety of Single-dose Pegfilgrastim for CD34 + Cell Mobilization in Healthy Volunteers: A Phase 2 Study. Transplantation. 2024 Apr 1;108(4):996-1003. doi: 10.1097/TP.0000000000004880. Epub 2024 Mar 23.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Pegfilgrastim	Protein / enzyme biologic	3.6 mg	Subcutaneous
Subject	Pegfilgrastim	Protein / enzyme biologic	7.2 mg	Subcutaneous

KRN125 for Mobilization of Hematopoietic Stem Cells

Summary

Timeline

Publications

Drugs

Indications